Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Earnings data Q3 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Medtronic's (MDT) InPen is a FDA as well as CE Mark-cleared smart insulin pen available for patients who require multiple daily injections.

Medtronic (MDT) Diabetes Arm Grows With Favorable InPen Data

DEFINE AFib Study Will Leverage Data from Medtronic Insertable Cardiac Monitors and Medtronic Discovery App™ with the Goal of Informing Atrial Fibrillation (AF) Management Strategies DUBLIN, June 29, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the initiation of the DEFINE AFib study, the company's first app-based research study. Using data collected from the LINQ family of insertable cardiac monitors (ICMs), the study aims to address unanswered questions around atrial fibrillation (AF) burden and its impact on patient outcomes, quality of life, and healthcare utilization.

Medtronic Launches App-Based Study to Better Understand Relationship Between Atrial Fibrillation Disease Burden and Impact on Patient Outcomes

Most of Medtronic (MDT) end markets are gradually returning to near-normal pre-COVID growth.

Medtronic (MDT) Global Market Share Rises Amid Pandemic Blues

Data Were Presented at the American Diabetes Association 81st Scientific Sessions DUBLIN, June 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced key clinical data from the virtual 81st annual American Diabetes Association Scientific Sessions. The presentations illustrated increases in Time in Range when using an InPen™ smart insulin pen, safety of an extended-wear infusion set that lasts up to 7 days, and patient satisfaction with the longer-wear infusion set.

Medtronic InPen™ Real-World Data and Extended Infusion Set* Pivotal Trial Results Demonstrate Strong Clinical Outcomes and Positive User Experience

Medtronic stock has seen an 8% rise so far this year, slightly underperforming the broader markets with the S&P 500 up 15%. While the Covid-19 pandemic weighed on the company's performance over the past few quarters, the opening up of economies would mean a rebound in demand for medical devices.

Medtronic Stock Remains Attractive At $125 Levels

GALWAY, Ireland--(BUSINESS WIRE)--Palliare Closes $8M Series A Funding Round

Palliare Completes $8m Series A Funding Round

DexCom

Tandem Diabetes Care

CGM device stocks Medtronic (MDT), Dexcom (DXCM) and Tandem Diabetes (TNDM) are expected to continue their run over the next few months.

Diabetes Space Thrives on CGM Devices in 2021: 3 Stocks in Focus

Medtronic (MDT) to begin patient registry for the Hugo RAS system following first successful patient procedure at Clinica Santa Maria in Chile.

Medtronic (MDT) Reports First Surgery With Hugo RAS System (Revised)

Medtronic (MDT) Reports First Surgery With Hugo RAS System

Citigroup

Crown Castle International

Eaton

NRG Energy

Despite ongoing inflation chatter, after spiking last week during the worst week for the markets since last October, interest rates have fallen back, and once again growth and income investors are looking for ideas.

5 BofA Securities US 1 List Stocks to Buy Now That Also Pay Very Dependable Dividends

DUBLIN, June 23, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced its participation at the American Diabetes Association (ADA) 81th scientific sessions virtual meeting, June 25-29, 2021. Medtronic will be participating in this year's ADA virtual sessions with seven data presentations, a product theater, two on-demand learning sessions, and a virtual exhibit.

Medtronic Announces Real-World Data on InPen™ and Extended Infusion Set* Pivotal Trial Data at the American Diabetes Association 81st Scientific Sessions

Medtronic's (MDT) Cardiac Cryoablation Catheters offer safe and effective substitute to antiarrhythmic drug therapy for the prevention of atrial arrythmia recurrence.

Medtronic (MDT) Gets Expanded FDA Nod for Cryoablation Catheters

SAP SE

Texas Instruments

If you want to enhance your likelihood to unearth companies that are in good shape from a financial standpoint, you may want to consider the following three stocks, as their trailing 12-month (TTM) Ebitda margins are outperforming the S&P 500's 10.7% as of the writing of this article.

A Trio of High Ebitda Margin Ratio Stock Picks

The Robotic Prostatectomy Marked the Start of the Hugo™ RAS System Global Patient Registry DUBLIN, June 22, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first patient procedure with the Hugo™ robotic-assisted surgery (RAS) system. The robotic prostatectomy was performed June 19 by urological surgeon Ruben Olivares, M.D.

First Procedure in the World with Medtronic Hugo™ Robotic-Assisted Surgery System Performed at Clínica Santa Maria in Chile

The FDA has granted expanded approval for Medtronic plc's (NYSE: MDT) cardiac cryoablation catheters for atrial fibrillation. The approval comes for Arctic Front Family of Cardiac Cryoablation Catheters to treat recurrent symptomatic paroxysmal atrial fibrillation (episodes that last less than seven continuous days) as an alternative to antiarrhythmic drug (AAD) therapy as an initial rhythm control strategy.

Medtronic Scores FDA Expanded Approval For Cardiac Cryoablation Catheters For Paroxysmal Atrial Fibrillation

- First and Only Approval to Indicate Cryoablation as an Initial Rhythm Control Strategy - Offers Safe, Effective Alternative to Antiarrhythmic Drug Therapy for the Prevention of Atrial Arrythmia Recurrence DUBLIN, June 21, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it received U.S. Food and Drug Administration (FDA) expanded approval for the Arctic Front™ Family of Cardiac Cryoablation Catheters for the treatment of recurrent symptomatic paroxysmal atrial fibrillation (episodes that last less than seven continuous days) as an alternative to antiarrhythmic drug (AAD) therapy as an initial rhythm control strategy. The expanded indication is based on results from STOP AF First, a prospective, multicenter randomized study that demonstrated superior efficacy of the Medtronic cryoablation procedure for preventing atrial arrhythmia recurrence compared to the use of AAD therapy.

Medtronic Receives FDA Expanded Approval for Arctic Front™ Family of Cardiac Cryoablation Catheters for Initial Use for Recurrent Symptomatic Paroxysmal Atrial Fibrillation

Air Products and Chemicals

Bristol-Myers

Cisco Systems

General Dynamics

Illinois Tool Works

JPMorgan Chase & Co

Stryker

T. Rowe Price Group

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: June 22-July 5, 2021

Becton, Dickinson and Co.

Boston Scientific

Edwards Lifesciences

Merit Medical Systems

These cardiology device stocks Medtronic (MDT), Boston Scientific (BSX), Edwards Lifesciences (EW), Merit Medical (MMSI), BD (BDX) are expected to continue their run over the next few months.

Cardiology Space Gains Momentum in 2021: 5 Stocks to Focus on

Portland General Electric

DENTSPLY SIRONA

All stocks have at least five fiscal years of dividend growth history and come from the U.S. Dividend Champions List.

3 Upcoming Dividend Increases Including Medtronic

Vanta utilizes Medtronic's (MDT) proprietary AdaptiveStim technology for personalized pain relief.

Medtronic (MDT) Progresses in SCS With FDA Nod for Vanta

Broadcom

Chubb

Hewlett Packard

Intercontinental Exchange

Main Street Capital

Philip Morris

UnitedHealth Group

This article series presents upcoming ex-dividend dates. We provide a summary table with relevant data and key statistics, including the next payout and pay date.

Upcoming Ex-Dividend Dates: June 15-28, 2021

American Airlines

Biogen

Agios Pharmaceuticals

Dow Inc

Nielsen Hlds

NetApp

Zoom Video

With the trading day about halfway over, the markets were moving higher, after being stuck in the doldrums for the first half of the week.

American Airlines, Biogen, Dow and More Thursday Afternoon Analyst Calls

Caterpillar

Clorox

The Dividend Aristocrats remain one of my favorite places to invest as these companies have raised dividend payments to shareholders for at least 25 consecutive years. Companies attaining membership in this group have business models that can withstand the impact of a recession as their products or services remain in high demand even in an economic downturn.

3 Dividend Aristocrats Growing Dividends

DUBLIN, June 10, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced it has received U.S. Food and Drug Administration (FDA) approval for Vanta™, a high performance recharge-free implantable neurostimulator (INS) with a device life that can be optimized up to 11 years. At comparable settings, the Vanta neurostimulator offers nearly twice the device life than competitive primary cell devices.1,2 It also utilizes Medtronic's proprietary AdaptiveStim™ technology for personalized pain relief that adapts to the patient's movement or body position using a built-in accelerometer.

Medtronic Announces FDA Approval of its Next Generation Recharge-Free Spinal Cord Stimulation Platform

STROKE AF trial shows Medtronic's (MDT) Reveal LINQ ICM has a seven-fold advantage in detecting AF compared to traditional standard of care in patients with large vessel or small vessel stroke.

News for Medtronic Stock (MDT)